SG

Surgery Partners, Inc.

SGRYHealthcareNASDAQ

Medical Care Facilities

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.31B
+6.2% YoY
Net Income
-$77.9M
+53.7% YoY
EBITDA
$565.5M
+12.8% YoY
Free Cash Flow
$199.1M

Scan Results

Daily timeframe
3 recent days hidden. Fresh signals are a Premium featureUpgrade →
DateIndicatorDetails
Jul 10 RSI OverboughtRSI 76.6, above 70, stock may be overbought
Jul 8 RSI OverboughtRSI 71.4, above 70, stock may be overbought
About Surgery Partners, Inc.

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. Valued at $2.09B, SGRY is a mid-cap name in its sector. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.

Key stats
Market Cap$2.09B
Fwd P/E24.44
EPS$-0.57
Beta1.89
52W Change-28.4%
ROE2.8%
Analysis

The company holds $182.3M in cash, though total debt stands at $4.04B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Annual free cash flow of $199.1M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on equity stands at 2.8%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.7% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $2.54B (2022) to $3.31B (2025), reflecting a 30% increase over the period.

With a beta above 1.5, SGRY tends to amplify broader market moves — both up and down. This higher volatility means larger price swings are common. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SGRY.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms